Altmetric

Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients

File Description SizeFormat 
MCD relapse Manuscript Final no tables or figures.docxAccepted version79.99 kBMicrosoft WordView/Open
Table 1 FINAL.docxSupporting information13.15 kBMicrosoft WordView/Open
Figure 1 Revision.docxSupporting information38.14 kBMicrosoft WordView/Open
Figure 2 revision.docxSupporting information15.74 kBMicrosoft WordView/Open
Figure 3 revision.docxSupporting information15.68 kBMicrosoft WordView/Open
Title: Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients
Authors: Dalla Pria, A
Pinato, D
Roe, J
Naresh, K
Nelson, M
Bower, M
Item Type: Journal Article
Abstract: Successful treatment of HIV-associated multicentric Castleman disease (HIV+MCD) with rituximab-based approaches has dramatically improved survival and reduced the risk of human herpesvirus 8 (HHV8)-associated lymphoma. Longer term outcomes including relapse rates have not been described and are important to establish the potential role of maintenance therapy. A prospective cohort of 84 patients with biopsy-proven HIV+MCD were treated with risk-stratified rituximab-based therapy. Four patients (5%) died of refractory HIV+MCD and 80 achieved clinical remission. The median follow-up for the 80 patients was 6.9 years and their 5-year overall survival was 92% (95% confidence interval [CI], 85 to 99). Eighteen have relapsed (all histologically confirmed), including 5 with concomitant HHV8-associated lymphoma and MCD at relapse. The 5-year relapse-free survival is 82% (95% CI, 72 to 92). No clinical or laboratory findings that were present at MCD diagnosis predicted subsequent relapse, and the median time to first relapse was 30 months (maximum, 10 years). There were no significant differences in clinicopathological features at initial diagnosis and at relapse. All patients were successfully retreated at relapse with rituximab-based therapy. Only 1 patient died of relapsed MCD (at fifth relapse 9.4 years after initial diagnosis). Despite the use of rituximab, the risk of developing HHV8-associated lymphoma was significantly elevated in this cohort, with an incidence of 11.4/1000 person-years. The relatively low relapse rate and high salvage rates at relapse reduce the potential benefit of maintenance therapy; this should only be advocated in the context of a clinical trial.
Issue Date: 13-Apr-2017
Date of Acceptance: 17-Jan-2017
URI: http://hdl.handle.net/10044/1/48324
DOI: https://dx.doi.org/10.1182/blood-2016-10-747477
ISSN: 0006-4971
Publisher: American Society of Hematology
Start Page: 2143
End Page: 2147
Journal / Book Title: BLOOD
Volume: 129
Issue: 15
Copyright Statement: © 2017 The American Society of Hematology. The article was published in Blood 2017 129:2143-2147; doi: https://doi.org/10.1182/blood-2016-10-747477
Sponsor/Funder: St Stephen's Aids Trust
Funder's Grant Number: N/A
Keywords: Science & Technology
Life Sciences & Biomedicine
Hematology
LYMPHOMA
VALGANCICLOVIR
SUPPRESSION
HHV-8
CELLS
TRIAL
Adult
Disease-Free Survival
Female
Follow-Up Studies
Giant Lymph Node Hyperplasia
HIV Seropositivity
Herpesviridae Infections
Herpesvirus 8, Human
Humans
Male
Recurrence
Retrospective Studies
Rituximab
Survival Rate
Immunology
1102 Cardiovascular Medicine And Haematology
1103 Clinical Sciences
1114 Paediatrics And Reproductive Medicine
Publication Status: Published
Appears in Collections:Division of Surgery
Division of Cancer
Department of Medicine
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx